Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
"We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasonedbusiness development executive, she has built a highly respected track recordand earned the trust of the pharmaceutical community. Diana will be astrategically important asset to our company. Furthermore, by bringing anextensive knowledge of the pharmaceutical industry and its regulatoryenvironment combined with confidence and multifaceted business experience, shewill continue to broaden and strengthen our relationship with our drugdevelopment partners."
"I am delighted to join Stason, a fast-growing and forward thinkingorganization," Ms. Wood said. "Today's product development landscape ischanging rapidly and paradigms are shifting towards a more technologicallydriven development process from the bench to market. Stason embraced thesechanges early on, reducing overall development time and costs. I look forwardto bringing new opportunities to Stason and to further expand our globalgrowth."
About Stason Pharmaceuticals:
Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into avertically integrated cGMP contract development organization with affiliatesand locations in Texas, Massachusetts, Japan, China and Taiwan that providecomplete turn-key drug development solutions for API, prototype and finalproduct, clinical supplies for all phases, and commercial production anddistribution. Stason also out-licenses internally developed technologies tocompanies worldwide. Stason is specialized in developing and processinghigh-potency products, including oncology drugs.
SOURCE Stason Pharmaceuticals, Inc.
You May Also Like